Top Page
CanSino Biologics, Inc. Class H
(6185)
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
CanSino Biologics, Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 971.73M | 846.34M | 345.18M | 1.03B | 4.30B | 24.89M |
| Gross Profit | 679.87M | 601.91M | -876.02M | -186.61M | 3.00B | 4.74M |
| EBITDA | -77.16M | -134.84M | -1.65B | -1.32B | 1.85B | -498.75M |
| Net Income | -142.04M | -378.88M | -1.48B | -909.43M | 1.91B | -396.64M |
Balance Sheet | ||||||
| Total Assets | 7.30B | 7.96B | 9.32B | 11.47B | 11.87B | 6.75B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 3.20B | 4.12B | 5.95B | 7.78B | 5.11B |
| Total Debt | 1.43B | 2.01B | 2.70B | 2.70B | 1.37B | 142.54M |
| Total Liabilities | 2.37B | 3.05B | 4.03B | 4.22B | 3.33B | 677.22M |
| Stockholders Equity | 4.93B | 4.91B | 5.27B | 6.75B | 8.00B | 6.07B |
Cash Flow | ||||||
| Free Cash Flow | -149.59M | -626.42M | -1.53B | -2.96B | 811.42M | -740.16M |
| Operating Cash Flow | 162.32M | -168.79M | -916.25M | -1.89B | 2.01B | -469.39M |
| Investing Cash Flow | 313.91M | 3.96M | -449.65M | -1.19B | -2.53B | -182.71M |
| Financing Cash Flow | -725.18M | -334.18M | -7.58M | 854.60M | 1.56B | 4.94B |
CanSino Biologics, Inc. Class H Technical Analysis
CanSino Biologics, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$233.73B | 44.46 | 16.09% | 0.97% | 8.68% | 0.82% | |
72 Outperform | HK$31.92B | 11.33 | 14.91% | 4.09% | -0.45% | 9.00% | |
68 Neutral | HK$28.59B | 9.40 | 5.90% | 2.95% | ― | ― | |
61 Neutral | HK$44.07B | 9.60 | 7.86% | 7.15% | 1.13% | -13.53% | |
53 Neutral | HK$74.73B | 15.55 | 6.75% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$13.51B | -57.08 | -2.79% | ― | 29.21% | 80.37% |
CanSino Biologics, Inc. Class H Corporate Events
CanSino Biologics has issued a forecast for 2025 indicating that revenue is expected to rise to between RMB1.04 billion and RMB1.08 billion, representing year-on-year growth of roughly 23% to 28%, driven largely by strong uptake of its Menhycia® MCV4 vaccine and enhanced commercialization efforts. The company expects to swing from a substantial loss in 2024 to a net profit attributable to shareholders of RMB24.5 million to RMB29.0 million in 2025, although it still anticipates a net loss after deducting non-recurring items, reflecting the significant impact of government grants and international funding on headline earnings; improved cost control, better coordination between production and sales, and higher gross margins underpin the improved profitability outlook and signal a strengthening operational and competitive position in China’s vaccine market.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has received approval from China’s National Medical Products Administration to begin clinical trials for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24), which is designed to protect individuals aged six weeks and older against diseases caused by 24 pneumococcal serotypes. The candidate, which uses covalent conjugation and dual carrier technology and has completed key production and formulation development steps, would be the first 24-valent pneumococcal conjugate vaccine on the global market if successfully developed, potentially strengthening CanSino’s competitive positioning in the high-value pneumococcal vaccine segment and signaling an important pipeline milestone for investors and industry stakeholders.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$35.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics has initiated a Phase I clinical trial for its DTcP-Hib-MCV4 combined vaccine, which targets diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and meningococcal groups ACYW135, and has completed enrollment of the first patient. The trial, designed to evaluate safety and immunogenicity in children aged two months to six years, is part of the company’s strategy to expand its combined vaccine portfolio and secure a differentiated competitive position in the pediatric vaccine market, though the company cautioned investors to exercise care when trading its shares at this stage of development.
The most recent analyst rating on (HK:6185) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. announced the successful passage of all resolutions at its 2025 second extraordinary general meeting, including amendments to the Articles of Association and the election of new independent non-executive directors. These changes, effective from November 27, 2025, are expected to enhance the company’s governance structure and strategic direction, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (HK:6185) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has initiated a Phase I clinical trial in Indonesia for its inhaled tuberculosis booster vaccine, marking the completion of the first patient enrollment. This innovative vaccine aims to enhance the efficacy of the existing Bacillus Calmette-Guerin vaccine by stimulating a stronger immune response in the lungs, potentially controlling latent infections and preventing new ones. The trial will assess the safety and immunogenicity of the vaccine in adults, leveraging the company’s expertise in inhalation technology developed for COVID-19 vaccines.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has announced its 2025 second extraordinary general meeting, where significant amendments to corporate governance policies and the company’s Articles of Association will be discussed. The meeting will also address the appointment of new independent non-executive directors and the utilization of reserves to offset losses, indicating a strategic move to strengthen its governance framework and financial stability.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has announced a proposal to use its reserves to offset accumulated losses amounting to approximately RMB1.45 billion as of December 31, 2024. This strategic move, approved by the Board of Directors and pending shareholder approval, aims to enhance the company’s ability to deliver investor returns and support its high-quality development by reducing its accumulated losses to zero.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has established a Remuneration and Assessment Committee to enhance its corporate governance structure. This committee is responsible for evaluating the performance and remuneration of directors and senior management, which is expected to improve transparency and accountability within the company.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has announced significant changes to its corporate governance structure, including the proposed cancellation of its Board of Supervisors and amendments to its Articles of Association and corporate governance rules. These changes aim to enhance the company’s governance standards and streamline operations, with the audit committee taking over the functions of the Board of Supervisors. The proposed changes are subject to approval by shareholders at an extraordinary general meeting.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has established an Audit Committee to enhance its governance structure and ensure effective oversight and management by the board of directors. This move is aimed at improving the company’s internal control systems, facilitating communication with external audit firms, and assessing risks related to significant investments. The committee will consist of non-executive directors, with a majority being independent, to ensure unbiased supervision and verification of audits.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has established a Nomination Committee to enhance its corporate governance by standardizing the nomination procedures for directors and senior management. This move aims to improve the board’s composition and align with relevant regulations, potentially strengthening the company’s governance structure and market position.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
CanSino Biologics Inc. has released its unaudited third-quarter financial report for the nine months ending September 30, 2025, showing a significant increase in operating revenue and net profit compared to the previous year. The company’s operating revenue rose by 22.13% to RMB 692.57 million, and net profit attributable to shareholders surged by 842.01% to RMB 14.44 million, indicating strong financial performance and potential positive implications for investors and stakeholders.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.